Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Drugmakers are growing frustrated with the National Health Service after a clawback tax unexpectedly soared, with ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

This Fool considers how two low-risk and well-established FTSE shares could offer stability and growth during a period of market volatility.

The stock market can be a scary place for those who aren’t prepared. Our writer outlines three ways we might avoid getting caught out.

Two FTSE 100 stocks in Harvey Jones' portfolio have suffered double-digit losses. He's standing by them for now, but he's ...

A recent example of content that inspired a positive response was the profiling of women in management within GSK, to mark International Women's Day which took place on 8th March. The theme of ...

While the deals done this week are important for the future direction of the industry – US company Gilead (US:GILD) inked the biggest, paying up to $1.7bn for Leo Pharma’s range of pre-clinical ...

Stocks across Asia lost ground on Monday as worries about Chinese AI company DeepSeek reverberated. The company's discounted ...